Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CMC Biologics Achieves Authorization for cGMP Commercial Manufacturing by DKMA

Published: Thursday, October 17, 2013
Last Updated: Thursday, October 17, 2013
Bookmark and Share
Copenhagen biopharmaceutical manufacturing facility expanded to support growing customer demand for clinical and commercial production.

CMC Biologics has received renewal of its manufacturing and importation authorization (MIA) for Good Manufacturing Practice (cGMP) production of clinical and commercial manufacturing from the Danish Medicines Agency (DKMA), a division of the Danish Health and Medicines Authority.

The DKMA inspected CMC Biologics’ optimized manufacturing and testing facilities in Copenhagen, Denmark in late May, and issued the certificate based on the positive outcome of the inspection.

"This important regulatory milestone helps drives our strategy to satisfy our customers’ growing clinical and commercial cGMP manufacturing requirements, and takes this site to the next level as a global leader in commercial production of protein therapeutics,” said Patricio Massera,
General Manager of CMC Biologics Copenhagen. “We are committed to the highest quality standards and extremely pleased with the results of the agency’s inspection.”

CMC Biologics made an important capital investment in its biopharmaceutical manufacturing facility which optimizes segregation of unit operations and improves flow of materials and personnel.

The enhanced layout now maintains a fully unidirectional return corridor and exit airlocks to achieve exceptional manufacturing quality standards.

The updated MIA is available on the EudraGMP database at http://eudragmp.ema.europa.eu; authorization number 26415.

Massera adds, “Our vision is to be considered the global market leader of customer satisfaction for contract biopharmaceutical process development and manufacturing services. This facility expansion and successful regulatory inspection represents another step toward making that vision a reality.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CMC Biologics, IDT Biologika Collaborate
Company has announced the collaboration will provide an efficient solution for development and manufacture of ADCs.
Saturday, February 27, 2016
CMC Biologics and OncoSynergy Enter into an Agreement
Agreement for accelerated process development and GMP manufacture of an investigational drug to combat Ebola.
Friday, December 19, 2014
CMC Biologics and OncoSynergy Enter into Agreement
Agreement to develop and manufacture material for IND enabling studies and phase I clinical trials.
Monday, December 23, 2013
CMC Biologics Acquires XOMA’s Bay Area Manufacturing Facility
Expansion designed to further support growing customer demand for cGMP clinical and commercial biologics production.
Tuesday, August 07, 2012
CMC Biologics Licenses its CHEF1® Expression System to Oxford BioTherapeutics
Agreement covers the research, development, and commercial use of the system by OBT.
Monday, January 02, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Gene Regulation in Brain May Explain Repetitive Behaviors in Rett Syndrome Patients
The research could be a key step in developing treatments to eliminate symptoms that drastically impair the quality of life in Rett patients.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Iron Nanoparticles Make Immune Cells Attack Cancer
Researchers accidentally discover that nanoparticles invented for anemia treatment can trigger the immune system’s ability to destroy tumor cells.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Uncovering Cancer’s ‘Invisibility Cloak’
Researchers discover cancer cell mechanism to become invisible to the body's immune system.
Genetic Impact of Endurance Training
Research has found that endurance training changes genetic activity in thousands of genes, giving rise to large number of altered RNA variants.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!